

Corporate Medical Policy

Genetic Testing of CADASIL Syndrome AHS – M2069

File Name: genetic_testing_of_cadasil_syndrome
Origination: 01/01/2019
Last Review: 1/2024

Description of Procedure or Service

Description

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetic small vessel disease in which mutations in *notch receptor 3 (NOTCH3)*, located on chromosome 19 (Joutel et al., 1996), result in a clinical syndrome of adult-onset migraines (frequently with aura), progressive strokes, and cognitive decline in adults leading to severe functional impairment by the seventh decade of life (Opherk et al., 2004; Zhu & Nahas, 2016).

Related Policies

General Genetic Testing, Germline Disorders AHS-M2145

*****Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.**

Policy

BCBSNC will provide coverage for genetic testing of CADASIL syndrome when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Genetic Testing of CADASIL Syndrome is covered

1. For individuals who have received genetic counseling and who have received a clinical diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) or for whom a definitive diagnosis cannot be made without genetic testing, genetic testing of *NOTCH3* to confirm the diagnosis of CADASIL is considered medically necessary.
2. For asymptomatic individuals who have a first- or second-degree relative (see Note 1) diagnosed with CADASIL syndrome, the following genetic testing is considered medically necessary:
 - A. Testing restricted to the known familial *NOTCH3* mutation.
 - B. Comprehensive *NOTCH3* sequencing only if the specific familial mutation is unknown.

NOTES:

Note 1: First-degree relatives include parents, full siblings, and children of the individual. Second-degree relatives include grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual.

Genetic Testing of CADASIL Syndrome AHS – M2069

When Genetic Testing of CADASIL Syndrome is not covered

For all other situations not discussed above, genetic testing for CADASIL syndrome is considered investigational.

Policy Guidelines

Background

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary small vessel disease and is characterized by granular osmiophilic material deposits surrounding blood vessels, a prominent thickening of the vessel wall by extracellular matrix accumulation, and a progressive loss of vascular smooth muscle cells (VSMCs) (Fernandez-Susavila et al., 2018; Ferrante et al., 2019; Monet-Lepretre et al., 2013). Small vessel diseases such as this are an important cause of stroke and vascular cognitive decline in adults (Chabriat et al., 2009). VSMC dysfunction may be caused by mutations in the *NOTCH3* gene, leading to irregularities in VSMC proliferation, cell cycle affliction, senescence, and cellular apoptosis (Dziewulska et al., 2018).

Individual symptoms, onset, and disease severity span a wide spectrum (Wang, 2018). Thus, descriptions of hereditary multi-infarct dementia, chronic familial vascular encephalopathy, and familial subcortical dementia, originally thought to be separate disorders, represent early reports of this condition (Dichgans, 2023). CADASIL usually presents with one or more of the following: dementia, psychiatric disturbances, migraine, and recurrent strokes (Chabriat et al., 2009; Dichgans et al., 1998; M.Wang, 2018). Rarer symptoms include lumbago, humpback, and Parkinson syndrome (Lim et al., 2019). Migraine with aura occurs in 55% of CADASIL cases and is often the initial manifestation of the disease (Di Donato et al., 2017). Subcortical ischemic attacks begin at a mean age of 47 years and present as lacunar syndromes (Adib-Samii et al., 2010; Dichgans et al., 1998). Accumulation of lacunae, which impact executive performance and function independence, strongly correlate to clinical severity (Ling et al., 2017). Cognitive impairment associated with CADASIL is progressive; a profile of frontal lobe dysfunction, declarative memory impairment suggestive of a retrieval deficit, and relatively preserved language is often evident with this disease (Harris & Filley, 2001). A concurrent stepwise deterioration due to recurrent strokes is also common (Rutten & Lesnik Oberstein, 2016). Mood disturbances are reported in approximately 30% of individuals (Adib-Samii et al., 2010; Dichgans et al., 1998). Further, apathy, which may be independent of depression, is reported in 40% of individuals (Reyes et al., 2009).

Genetic linking of the disorder to chromosome 19 was first recognized in 1993, and the identification of the *NOTCH3* gene from the CADASIL mapped region was later discovered in 1996 (Ping & Zhao, 2018). While CADASIL was originally diagnosed via neuroimaging techniques, such as magnetic resonance imaging (MRI), the identification of the distinctive missense mutations in *NOTCH3* has allowed genetic testing to debut as the current gold standard for CADASIL diagnostics (Rutten & Lesnik Oberstein, 2016). However, MRI testing for the detection of cerebral white matter changes in the brain is still used to assist in CADASIL diagnoses; most often, MRI imaging is used as a diagnostic measure before symptoms present (Ferrante et al., 2019).

Missense mutations in the *NOTCH3* gene typically lead to the gain or loss of a cysteine, therefore resulting in an unpaired number of cysteine residues in one of 34 highly conserved epidermal growth factor-like repeat (EGFr) domains (Joutel et al., 1996; Papakonstantinou et al., 2019; Rutten et al., 2014). This leads to an increased multimerization tendency of mutant NOTCH3 (Duering et al., 2011), toxic accumulation of the protein and extracellular matrix in disulfide cross-linked detergent-insoluble aggregates (Monet-Lepretre et al., 2013), altered neurovascular coupling (Huneau et al., 2018), and ultimately reduced cerebral blood flow, recurrent stroke, and vascular dementia (Rutten et al., 2016).

Genetic Testing of CADASIL Syndrome AHS – M2069

However, certain *NOTCH3* mutations do not present with a cysteine change; this type of non-cysteine mutation can cause a great loss of structure in the NOTCH3 protein (Papakonstantinou et al., 2019).

More than 200 *NOTCH3* mutations have been reported since its original discovery in the development of CADASIL syndrome in 1996; some of these mutations result in a phenotypic change while some present as a silent mutation. A few prevalent *NOTCH3* variants include the 34 identified in EGFr. EGFr 1–6 pathogenic variants are more common in the CADASIL population than EGFr 7–34 pathogenic variants; unfortunately, patients with EGFr 1–6 variants tend to present with more severe symptoms and phenotypes (Papakonstantinou et al., 2019; Rutten et al., 2018). These severe symptoms include stroke onset an average of 12 years earlier and overall lower survival rates (Papakonstantinou et al., 2019).

The prevalence of the disease has been estimated to be at 0.8 to five per 100,000 individuals (Moreton et al., 2014; Narayan et al., 2012; Razvi et al., 2005). However, many suspect that these numbers are underestimates. A more recent investigation of the frequency of the characteristic missense CADASIL mutations in a public database found a total prevalence of 3.4/1000 (Rutten et al., 2016).

Currently, no efficient treatment options to cure or prevent CADASIL syndrome are available (Hack et al., 2019; NORD, 2019); however, recent studies have shown proof of concept for a novel application of exon skipping and are a first step towards the development of a rational therapeutic approach to treat up to 94% of CADASIL-causing mutations (Rutten et al., 2016). Further, neurofilament light chains have now been identified as a promising CADASIL biomarker and can be detected in the serum of affected patients (Ferrante et al., 2019).

Analytical Validity

There are no established diagnostic criteria for CADASIL. The phenotype is highly variable, and although imaging may be suggestive, no characteristic is pathognomonic; genetic testing remains the gold standard for diagnosis (Rutten & Lesnik Oberstein, 2016; Wang, 2018). As a heterozygous pathogenic variant in the *NOTCH3* protein coding gene is well established as a main reason for CADASIL development, a CADASIL diagnosis is generally delivered based on molecular genetic testing or electron microscopy and immunohistochemistry results. Molecular genetic testing approaches may include both gene-targeted testing and in-depth genomic testing, such as exome sequencing and genome sequencing (Hack et al., 2019; Papakonstantinou et al., 2019).

Immunohistochemistry combined with electron microscopy of skin biopsy can be useful when molecular testing is not definitive (Rutten & Lesnik Oberstein, 2016). Immunohistochemistry assay of a skin biopsy sample for the accumulation of NOTCH3 protein in the walls of small blood vessels (Joutel et al., 2001) has an estimated sensitivity and specificity at 85-90% and 95-100%, respectively (Lesnik Oberstein et al., 2003). Detection of granular osmiophilic material deposits (GOM) containing the ectodomain of the *NOTCH3* gene by electron microscopy (del Rio-Espinola et al., 2009; Muqtadar & Testai, 2012) had a sensitivity of 45% and a specificity of 100% (Brulin et al., 2002; Malandrini et al., 2007; Markus et al., 2002).

Magnetic resonance imaging (MRI) is useful to demonstrate radiologic features of CADASIL, including recent lunar infarctions and white matter hyperintensities. Computed tomography (CT) scans are less sensitive than MRI in this regard (Dichgans, 2023). MRI may also provide prognostic information. Brain lesions in CADASIL patients tend to precede symptoms by 10 to 15 years; however, a normal MRI in the fourth decade of life should not automatically rule out CADASIL syndrome even though most patients exhibit an abnormal MRI by age 35 (Samoës et al., 2016). White matter hyperintensities on MRI can be visualized in those aged 21 years and older, and lesion volume correlates with the level of disability and three-year clinical course of CADASIL (Jouvent et al., 2016). Isolated T2 hyperintensities involving the temporal poles can differentiate CADASIL from chronic microvascular ischemia due to hypertension with a sensitivity and specificity of 95% and 80%, respectively (O'Sullivan et al., 2001). Cerebral microbleeds visible on T2 weighted MRI images

Genetic Testing of CADASIL Syndrome AHS – M2069

detected in 36% of patients with CADASIL were independently associated with an increased risk of incident ischemic stroke and may be a marker for a subgroup of patients with CADASIL who have a more severe or advanced form of the disease (Puy et al., 2017).

Guo et al. (2021) studied the role of *NOTCH3* gene mutations and variants in Alzheimer Disease (AD) and subcortical vascular dementia (SVaD). CADASIL is a common etiology of SVaD. 667 AD patients, 96 SVaD patients, and 365 healthy control participants, all recruited from the Southern Han Chinese population, were included in the study. The authors performed targeted capture sequencing on *NOTCH3* and adjacent intron regions. “Five known pathogenic variants (p.R182C, p.C201S, p.R544C, p.R607C, and p.R1006C) and two novel likely pathogenic variants (p.C201F and p.C1061F) were detected in 16 SVaD patients.” No pathogenic variants were found in AD patients. The authors concluded that the “findings broaden the mutational spectrum of *NOTCH3* and validate the pathogenic role of *NOTCH3* mutations in SVaD, but do not support the notion that *NOTCH3* variation influences the risk of AD” (Guo et al., 2021).

Cho et al. (2021) performed an analysis on whole-exome sequencing data from 200,632 participants in the UK Biobank. The authors note that CADASIL is considered rare, but there is a higher frequency of cysteine-altering *NOTCH3* variants which could increase risk of apparently sporadic lacunar stroke. The authors compared frequency of stroke, vascular dementia, clinical features of CADASIL, and MRI white matter hyperintensity volume between carriers and non-carriers of 67 cysteine-altering *NOTCH3* variants. “*NOTCH3* variant carriers had increased risk of stroke (OR: 2.33, p=0.0004) and vascular dementia (OR: 5.00, p=0.007), and increased white matter hyperintensity volume (standardised difference: 0.52, p<0.001) and white matter ultrastructural damage on diffusion MRI (standardised difference: 0.72, p<0.001).” The authors concluded that “cysteine-changing *NOTCH3* variants are more common in the general population than expected from CADASIL prevalence and are risk factors for apparently 'sporadic' stroke and vascular dementia” (Cho et al., 2021).

Gravesteyn et al. (2021) studied the effect of *NOTCH3* variant position on *NOTCH3* protein aggregation load. Vascular *NOTCH3* aggregation was measured in skin biopsies and brain tissue from CADASIL patients. “CADASIL patients with an EGFr 7-34 variant have significantly less vascular *NOTCH3* aggregation than patients with an EGFr 1-6 variant.” The authors concluded that *NOTCH3* variant position may be a factor that underlies differences in CADASIL disease severity (Gravesteyn et al., 2021).

Clinical Validity and Utility

One study has reported that the sequence analysis of *NOTCH3* is 95-100% sensitive and 100% specific to establish the diagnosis of CADASIL (Dotti et al., 2005; Peters et al., 2005; Tikka et al., 2009; Yin et al., 2015). A preliminary scale was proposed to screen for patients who should undergo *NOTCH3* gene analysis with a sensitivity of 96.7% and a specificity of 74.2% (Pescini et al., 2012). Another study of Russian patients with clinically suspected CADASIL concluded that careful assessment of genealogical, clinical, and neuroimaging data in patients with lacunar stroke can help select patients with a high probability of finding mutations on genetic screening (Abramycheva et al., 2015). In the absence of clinical features suggestive of CADASIL, screening of patients with lacunar stroke, leukoarosis, and migraine have low yield (de Vries et al., 2009; Dong et al., 2003).

As individual symptoms and disease severity span a wide spectrum, it must be noted that symptom onset alone cannot warrant a CADASIL syndrome diagnosis. Researchers previously screened 123 patients who exhibited two common CADASIL symptoms: lacunar stroke and transient ischemic attack. These participants were genetically tested for CADASIL; it was determined that only 12.5% had a *NOTCH3* mutation, showing that common CADASIL symptoms are shared with many other disorders (Bersano et al., 2018). This highlights the importance of genetic testing as a diagnostic measure. Further, three features were found to be significantly associated with a CADASIL diagnosis: “A family history of stroke, the presence of dementia and external capsule lesions on MRI” (Bersano et al., 2018).

Genetic Testing of CADASIL Syndrome AHS – M2069

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) was first diagnosed by visualizing granular osmiophilic material (GOM) in the tunica media of small arteries through light microscopy. Although GOM deposit is the pathological hallmark of CADASIL, *NOTCH3* genetic sequencing is the confirmative diagnostic tool. While most genetic tests use Sanger sequencing methods to target specific *NOTCH3* exons, next-generation sequencing (NGS) and whole exome sequencing (WES) have proven to deliver greater efficacy. One study has reported that NGS and WES have increased sensitivity to detect low frequency variants of *NOTCH3* mutations compared to Sanger sequencing. Through Sanger sequencing, 10.8% of tests were able to identify *NOTCH3* mutations compared to 15.8% of tests identifying mutations through next-generation sequencing. With NGS, the results were in concordance with Sanger sequencing, but it extended the capacity to detect mutations and previously unreported variants. As diagnostic sequencing techniques continue to advance, NGS and WES may play an important role in identifying other genes involved with CADASIL (Dunn et al., 2020).

Rutten et al. (2018) analyzed the effect of *NOTCH3* pathogenic variant (PV) location on CADASIL disease variability. The authors correlated PV position with brain MRI lesion load, age of first stroke, and survival on 664 European CADASIL patients. “CADASIL patients with an EGFr 1–6 pathogenic variant have a 12-year earlier onset of stroke than those with an EGFr 7–34 pathogenic variant, lower survival, and higher white matter hyperintensity volumes.” The authors concluded that *NOTCH3* PV location is “the most important determinant of CADASIL disease severity” (Rutten et al., 2018).

Mukai et al. (2020) correlated genotypes and phenotypes of 179 Japanese CADASIL probands. The authors identified 68 mutations, “p.Cys388Arg, p.Cys435Phe, p.Gly481Cys, p.Cys743Tyr, and p.Cys1009Phe were novel ones.” The authors then analyzed genotype-phenotype correlations on the three most common mutations. “p.Arg141Cys showed typical CADASIL phenotypes, whereas p.Arg75Pro showed mild and atypical phenotypes, a low frequency of stroke/TIA [transient ischemic attack], high frequency of hypertension, and low frequency of temporal pole lesions. p.Arg182Cys showed various initial symptoms other than stroke/TIA.” The authors also studied mutation location and the age of stroke/TIA onset, and found that mutations of EGFr 1-6 (excluding p.Arg75Pro) were significantly correlated with a younger age of stroke/TIA onset than mutations in EGFr 7-43. The authors concluded that the data clarified genotype-phenotype correlations and the effect of mutation location on the age of stroke/TIA onset in Japanese CADASIL probands (Mukai et al., 2020).

Hack et al. (2020) performed a cross-sectional study using 118 participants with a *NOTCH3* cysteine altering variant and 184 age- and sex-matched control participants. Clinical, neuroimaging, and whole-exome data was compared. There was no difference in dementia, mild cognitive impairment, migraine with aura, or depression prevalence. Participants with a *NOTCH3* cysteine altering variant had a higher risk of stroke, white matter hyperintensity, and lacunas after age 65. The authors note that the classic mid-adult onset CADASIL phenotype was not reported, suggesting “*NOTCH3* variants do not only cause the rate and more severe hereditary CADASIL but are much more commonly associated with a milder [cerebral small vessel disease] SVD phenotype, specifically when these variants are located in EGFr 7 to 35” (Hack et al., 2020).

Liu et al. (2021) tracked clinical and MRI data of three patients from a family in China over seven years. Genetic tests confirmed CADASIL diagnosis on all three participants, including a novel mutation of p.C533S on exon 10 of *NOTCH3*. The same heterozygous mutations were detected across family members. The authors conclude that there is “distinct heterogeneity of CADASIL patients in the same family with the same mutation” (Liu et al., 2021).

Chen et al. (2021) assessed the diagnostic utility of using NGS and MRI data for the diagnosis of adult onset leukodystrophy. The authors used a panel of 200 neurodegeneration-related genes and an MRI brain-based diagnostic algorithm from 45 patients with young-onset cognitive impairment with leukodystrophy. All the patients with an established genetic diagnosis had MRI brain patterns consistent with their diagnosis. A total of 51.4% of patients with MRI changes consistent with vascular cognitive impairment secondary to small vessel disease (VCI-SVD) had pathogenic variants (89.5% of which were pathogenic *NOTCH3* and 11.5% of which were *HTRA1* variants). The authors

Genetic Testing of CADASIL Syndrome AHS – M2069

concluded that the results “demonstrated a high diagnostic utility incorporating a targeted neurodegeneration gene panel and MRI-based diagnostic algorithms in young-onset cognitive impairment patients with leukodystrophy” (Chen et al., 2021).

Anisetti et al. (2023) gathered the electronic medical records (EMR) of adult patients with confirmed CADASIL disease to analyze the use of a recently proposed grading system. A grade of zero (asymptomatic), Grade One (migraine only), Grade Two (stroke, TIA, or MCI), Grade Three (gait assistance or dementia) or Grade 4 (bedbound or end-stage) was given to each patient. The inter-rater reliability of grading was also assessed with an 81.8% agreement on ratings. Results showed that those patients who received a lower grade on the CADASIL scale were younger (49.5 vs. 61.9 years) and were less likely to have hypertension and/or diabetes mellitus. Higher ratings were correlated with increased vascular risk factors. The authors concluded that a CADASIL grading system based on symptoms was a reliable categorization of patients to assess higher vascular risk factor burden (Anisetti et al., 2023).

Predictive Testing of At-Risk Family Members

For an asymptomatic individual, knowledge of mutation status will generally not lead to any management changes that can prevent or delay the onset of the disorder. Avoiding tobacco use may be a factor that delays onset of disease, but this is a general recommendation that is not altered by genetic testing. Goldman (2015) has suggested that asymptomatic family members follow the guidelines for presymptomatic testing for Huntington disease (HDSA, 2016).

Genetic testing for CADASIL may assist decision making in areas such as employment choices and reproductive decision making. However, the impact of these decisions on health outcomes is uncertain. Further, the testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals (Rutten & Lesnik Oberstein, 2016). Initial data from Reyes et al. (2012) show that predictive testing is rarely requested and has a high dropout rate.

Di Donato et al. (2017) state that the MRI of an unaffected family member could have a similar impact to a genetic test because MRIs are able to accurately predict CADASIL disease development before symptoms present. Therefore, the potential implications of MRI testing should be shared before this type of testing is completed.

Guidelines and Recommendations

American Heart Association (AHA) and American Stroke Association (ASA)

The American Heart Association and American Stroke Association do not provide any recommendations on rare genetic causes of cerebral small vessel disease, such as CADASIL, but they do provide suggestions on when rare genetic causes could be suspected. They suggest that the diagnosis could be made based on testing for mutations in the *NOTCH3* gene (Kleindorfer et al., 2021; Powers et al., 2019; Smith et al., 2017).

European Federation of Neurological Societies (EFNS)

The European Federation of Neurological Societies guideline on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias notes that most *NOTCH3* mutations occur within exons three and four and suggests direct sequencing of these two exons if clinical suspicion is high (Burgunder et al., 2010).

United States Preventive Services Task Force (USPSTF)

Genetic Testing of CADASIL Syndrome AHS – M2069

As of September 19, 2023, the USPSTF has not published guidelines for the genetic testing of CADASIL patients.

European Academy of Neurology (EAN)

The European Academy of Neurology (EAN) released guidelines for monogenic cerebral small-vessel disease (cSVD), including diagnosis and management of CADASIL. EAN suggests that the first line diagnosis for CADASIL should be genetic testing, but diagnosis can also be established by skin biopsy with electron microscopy revealing granular osmiophilic material (GOM). Most *NOTCH3* variants causing CADASIL are due to a loss or gain of a cysteine in the EGFR repeats. Some non-cysteine changing variants have been reported, but most of these non-cysteine changing variants do not lead to a diseased state. If genetic testing reveals a non-cysteine changing variant, electron microscopy to visualize GOM is a useful tool to confirm CADASIL diagnosis. If the *NOTCH3* variant is of unknown significance, CADASIL diagnosis can be established with skin biopsy via electron microscopy or immunohistochemistry of the *NOTCH3* extracellular domain. The guideline recommends “considering” a CADASIL diagnosis in any patient with “unexplained symmetrical periventricular WMHs [white matter hyperintensities] and a positive family history of migraine with aura, stroke, mood disorders or dementia.” The guideline also notes that CADASIL cannot be ruled out in the presence of “common cerebrovascular risk factors and extensive WMHs” or in “the absence of a medical or family history of migraine with aura.” The guideline remarks that “although most patients have a family history, if the clinical and imaging phenotype is consistent with CADASIL the diagnosis should be considered” (Mancuso et al., 2020).

Overall, the EAN remarks that “CADASIL can only be definitively confirmed by genetic testing, revealing a *NOTCH3* mutation altering the number of cysteines in one of the 34 EGFR domains of the NOTCH3 protein” (Mancuso et al., 2020).

National Organization for Rare Diseases (NORD)

The National Organization for Rare Diseases released diagnosis guidelines on the disease. “CADASIL is based on symptoms, family history, and brain MRI lesions compatible with the disease. The CADASIL diagnosis can only be confirmed by DNA testing of blood samples for characteristic mutations in the *NOTCH3* gene or by identifying granular osmiophilic material (GOM) inclusions on a skin biopsy” (Orjuela, 2019).

State and Federal Regulations, as applicable

Food and Drug Administration (FDA) Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 81406

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

Genetic Testing of CADASIL Syndrome AHS – M2069

- Abramycheva, N., Stepanova, M., Kalashnikova, L., Zakharova, M., Maximova, M., Tanashyan, M., Lagoda, O., Fedotova, E., Klyushnikov, S., Kononov, R., Sakharova, A., & Illarioshkin, S. (2015). New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). *J Neurol Sci*, 349(1-2), 196-201. <https://doi.org/10.1016/j.jns.2015.01.018>
- Adib-Samii, P., Brice, G., Martin, R. J., & Markus, H. S. (2010). Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. *Stroke*, 41(4), 630-634. <https://doi.org/10.1161/STROKEAHA.109.568402>
- Anisetti, B., Greco, E., Stojadinovic, E., Goldstein, E. D., Sakusic, A., Badi, M. K., Liu, M. D., Lin, M. P., Chiang, C. C., Elahi, F. M., Worrall, B. B., Petrosian, D., Ross, O., & Meschia, J. F. (2023). Novel grading system for CADASIL severity: A multicenter cross-sectional study. *Cereb Circ Cogn Behav*, 5, 100170. <https://doi.org/10.1016/j.cccb.2023.100170>
- Bersano, A., Bedini, G., Markus, H. S., Vitali, P., Colli-Tibaldi, E., Taroni, F., Gellera, C., Baratta, S., Mosca, L., Carrera, P., Ferrari, M., Cereda, C., Grieco, G., Lanfranconi, S., Mazucchelli, F., Zarcone, D., De Lodovici, M. L., Bono, G., Boncoraglio, G. B., . . . Candelise, L. (2018). The role of clinical and neuroimaging features in the diagnosis of CADASIL. *J Neurol*, 265(12), 2934-2943. <https://doi.org/10.1007/s00415-018-9072-8>
- Brunlin, P., Godfraind, C., Leteurtre, E., & Ruchoux, M. M. (2002). Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. *Acta Neuropathol*, 104(3), 241-248. <https://doi.org/10.1007/s00401-002-0530-z>
- Burgunder, J. M., Finsterer, J., Szolnoki, Z., Fontaine, B., Baets, J., Van Broeckhoven, C., Di Donato, S., De Jonghe, P., Lynch, T., Mariotti, C., Schols, L., Spinazzola, A., Tabrizi, S. J., Tallaksen, C., Zeviani, M., Harbo, H. F., & Gasser, T. (2010). EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. *Eur J Neurol*, 17(5), 641-648. <https://doi.org/10.1111/j.1468-1331.2010.02985.x>
- Chabriat, H., Joutel, A., Dichgans, M., Tournier-Lasserre, E., & Boussier, M. G. (2009). Cadasil. *Lancet Neurol*, 8(7), 643-653. [https://doi.org/10.1016/S1474-4422\(09\)70127-9](https://doi.org/10.1016/S1474-4422(09)70127-9)
- Chen, Z., Tan, Y. J., Lian, M. M., Tandiono, M., Foo, J. N., Lim, W. K., Kandiah, N., Tan, E. K., & Ng, A. S. L. (2021). High Diagnostic Utility Incorporating a Targeted Neurodegeneration Gene Panel With MRI Brain Diagnostic Algorithms in Patients With Young-Onset Cognitive Impairment With Leukodystrophy. *Front Neurol*, 12, 631407. <https://doi.org/10.3389/fneur.2021.631407>
- Cho, B. P. H., Nannoni, S., Harshfield, E. L., Tozer, D., Gräf, S., Bell, S., & Markus, H. S. (2021). NOTCH3 variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants. *J Neurol Neurosurg Psychiatry*, 92(7), 694-701. <https://doi.org/10.1136/jnnp-2020-325838>
- de Vries, B., Frants, R. R., Ferrari, M. D., & van den Maagdenberg, A. M. (2009). Molecular genetics of migraine. *Hum Genet*, 126(1), 115-132. <https://doi.org/10.1007/s00439-009-0684-z>
- del Rio-Espinola, A., Mendioroz, M., Domingues-Montanari, S., Pozo-Rosich, P., Sole, E., Fernandez-Morales, J., Fernandez-Cadenas, I., & Montaner, J. (2009). CADASIL management or what to do when there is little one can do. *Expert Rev Neurother*, 9(2), 197-210. <https://doi.org/10.1586/14737175.9.2.197>
- Di Donato, I., Bianchi, S., De Stefano, N., Dichgans, M., Dotti, M. T., Duering, M., Jouvent, E., Korczyn, A. D., Lesnik-Oberstein, S. A. J., Malandrini, A., Markus, H. S., Pantoni, L., Penco, S., Rufa, A., Sinanović, O., Stojanov, D., & Federico, A. (2017). Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. *BMC Med*, 15. <https://doi.org/10.1186/s12916-017-0778-8>
- Dichgans, M. (2023, July 11). *Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)*. <https://www.uptodate.com/contents/cerebral-autosomal-dominant-arteriopathy-with-subcortical-infarcts-and-leukoencephalopathy-cadasil>
- Dichgans, M., Mayer, M., Uttner, I., Bruning, R., Muller-Hocker, J., Rungger, G., Ebke, M., Klockgether, T., & Gasser, T. (1998). The phenotypic spectrum of CADASIL: clinical findings in 102 cases. *Ann Neurol*, 44(5), 731-739. <https://doi.org/10.1002/ana.410440506>
- Dong, Y., Hassan, A., Zhang, Z., Huber, D., Dalageorgou, C., & Markus, H. S. (2003). Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis. *Stroke*, 34(1), 203-205. <https://www.ncbi.nlm.nih.gov/pubmed/12511775>

Genetic Testing of CADASIL Syndrome AHS – M2069

- Dotti, M. T., Federico, A., Mazzei, R., Bianchi, S., Scali, O., Conforti, F. L., Sprovieri, T., Guidetti, D., Aguglia, U., Consoli, D., Pantoni, L., Sarti, C., Inzitari, D., & Quattrone, A. (2005). The spectrum of Notch3 mutations in 28 Italian CADASIL families. *J Neurol Neurosurg Psychiatry*, *76*(5), 736-738. <https://doi.org/10.1136/jnnp.2004.048207>
- Duering, M., Karpinska, A., Rosner, S., Hopfner, F., Zechmeister, M., Peters, N., Kremmer, E., Haffner, C., Giese, A., Dichgans, M., & Opherk, C. (2011). Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. *Hum Mol Genet*, *20*(16), 3256-3265. <https://doi.org/10.1093/hmg/ddr237>
- Dunn, P. J., Maksemous, N., Smith, R. A., Sutherland, H. G., Haupt, L. M., & Griffiths, L. R. (2020). Investigating diagnostic sequencing techniques for CADASIL diagnosis. *Hum Genomics*, *14*(1), 2. <https://doi.org/10.1186/s40246-019-0255-x>
- Dziewulska, D., Nycz, E., Rajczewska-Oleszkiewicz, C., Bojakowski, J., & Sulejczak, D. (2018). Nuclear abnormalities in vascular myocytes in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). *Neuropathology*, *38*(6), 601-608. <https://doi.org/10.1111/neup.12519>
- Fernandez-Susavila, H., Mora, C., Aramburu-Nunez, M., Quintas-Rey, R., Arias, S., Collado, M., Lopez-Arias, E., Sobrino, T., Castillo, J., Dell'Era, P., & Campos, F. (2018). Generation and characterization of the human iPSC line IDISi001-A isolated from blood cells of a CADASIL patient carrying a NOTCH3 mutation. *Stem Cell Res*, *28*, 16-20. <https://doi.org/10.1016/j.scr.2018.01.023>
- Ferrante, E. A., Cudrici, C. D., & Boehm, M. (2019). CADASIL: new advances in basic science and clinical perspectives. *Curr Opin Hematol*, *26*(3), 193-198. <https://doi.org/10.1097/moh.0000000000000497>
- Goldman, J. S. (2015). Genetic testing and counseling in the diagnosis and management of young-onset dementias. *Psychiatr Clin North Am*, *38*(2), 295-308. <https://doi.org/10.1016/j.psc.2015.01.008>
- Gravesteijn, G., Hack, R. J., Mulder, A. A., Cerfontaine, M. N., van Doorn, R., Hegeman, I. M., Jost, C. R., Rutten, J. W., & Lesnik Oberstein, S. A. J. (2021). NOTCH3 variant position is associated with NOTCH3 aggregation load in CADASIL vasculature. *Neuropathol Appl Neurobiol*. <https://doi.org/10.1111/nan.12751>
- Guo, L., Jiao, B., Liao, X., Xiao, X., Zhang, W., Yuan, Z., Liu, X., Zhou, L., Wang, X., Zhu, Y., Yang, Q., Wang, J., Tang, B., & Shen, L. (2021). The role of NOTCH3 variants in Alzheimer's disease and subcortical vascular dementia in the Chinese population. *CNS Neurosci Ther*, *27*(8), 930-940. <https://doi.org/10.1111/cns.13647>
- Hack, R., Rutten, J., & Lesnik Oberstein, S. A. J. (2019). CADASIL. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews*(R). University of Washington, Seattle.
- Hack, R. J., Rutten, J. W., Person, T. N., Li, J., Khan, A., Griessenauer, C. J., Abedi, V., Lesnik Oberstein, S. A. J., & Zand, R. (2020). Cysteine-Altering NOTCH3 Variants Are a Risk Factor for Stroke in the Elderly Population. *Stroke*, *51*(12), 3562-3569. <https://doi.org/10.1161/strokeaha.120.030343>
- Harris, J. G., & Filley, C. M. (2001). CADASIL: neuropsychological findings in three generations of an affected family. *J Int Neuropsychol Soc*, *7*(6), 768-774. <https://www.ncbi.nlm.nih.gov/pubmed/11575598>
- HDSA. (2016). *HDSA Genetic Testing Protocol for HD* <http://hdsa.org/wp-content/uploads/2015/02/HDSA-Gen-Testing-Protocol-for-HD.pdf>
- Huneau, C., Houot, M., Joutel, A., Beranger, B., Giroux, C., Benali, H., & Chabriat, H. (2018). Altered dynamics of neurovascular coupling in CADASIL. *Ann Clin Transl Neurol*, *5*(7), 788-802. <https://doi.org/10.1002/acn3.574>
- Joutel, A., Corpechot, C., Ducros, A., Vahedi, K., Chabriat, H., Mouton, P., Alamowitch, S., Domenga, V., Cecillon, M., Marechal, E., Maciazek, J., Vayssiere, C., Cruaud, C., Cabanis, E. A., Ruchoux, M. M., Weissenbach, J., Bach, J. F., Bousser, M. G., & Tournier-Lasserre, E. (1996). Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. *Nature*, *383*(6602), 707-710. <https://doi.org/10.1038/383707a0>
- Joutel, A., Favrole, P., Labauge, P., Chabriat, H., Lescoat, C., Andreux, F., Domenga, V., Cecillon, M., Vahedi, K., Ducros, A., Cave-Riant, F., Bousser, M. G., & Tournier-Lasserre, E. (2001). Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. *Lancet*, *358*(9298), 2049-2051. [https://doi.org/10.1016/S0140-6736\(01\)07142-2](https://doi.org/10.1016/S0140-6736(01)07142-2)
- Jouvent, E., Duchesnay, E., Hadj-Seleem, F., De Guio, F., Mangin, J. F., Herve, D., Duering, M., Ropele, S., Schmidt, R., Dichgans, M., & Chabriat, H. (2016). Prediction of 3-year clinical course in CADASIL. *Neurology*, *87*(17), 1787-1795. <https://doi.org/10.1212/WNL.0000000000003252>
- Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M.,

Genetic Testing of CADASIL Syndrome AHS – M2069

- Santangeli, P., Sharrief, A. Z., Smith, S. C., Jr., Turan, T. N., & Williams, L. S. (2021). 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*, *52*(7), e364-e467. <https://doi.org/10.1161/str.0000000000000375>
- Lesnik Oberstein, S. A., van Duinen, S. G., van den Boom, R., Maat-Schieman, M. L., van Buchem, M. A., van Houwelingen, H. C., Hegeman-Kleinn, I. M., Ferrari, M. D., Breuning, M. H., & Haan, J. (2003). Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. *Acta Neuropathol*, *106*(2), 107-111. <https://doi.org/10.1007/s00401-003-0701-6>
- Lim, H. K., Millar, Z. A., & Zaman, R. (2019). CADASIL and Bipolar Affective Disorder. *Psychiatr Danub*, *31*(Suppl 3), 591-594.
- Ling, Y., De Guio, F., Duering, M., Jouvent, E., Herve, D., Godin, O., Dichgans, M., & Chabriat, H. (2017). Predictors and Clinical Impact of Incident Lacunes in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. *Stroke*, *48*(2), 283-289. <https://doi.org/10.1161/strokeaha.116.015750>
- Liu, Y., Huang, S., Yu, L., Li, T., Diao, S., Chen, Z., Zhou, G., Sheng, X., Xu, Y., & Fang, Q. (2021). A Chinese CADASIL Family with a Novel Mutation on Exon 10 of Notch3 Gene. *J Stroke Cerebrovasc Dis*, *30*(8), 105674. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105674>
- M.Wang, A. I. o. o. p. (2018). *Handbook of Clinical Neurology* (Vol. 148). <https://www.sciencedirect.com/science/article/pii/B9780444640765000478>
- Malandrini, A., Gaudio, C., Gambelli, S., Berti, G., Serni, G., Bianchi, S., Federico, A., & Dotti, M. T. (2007). Diagnostic value of ultrastructural skin biopsy studies in CADASIL. *Neurology*, *68*(17), 1430-1432. <https://doi.org/10.1212/01.wnl.0000264018.46335.c8>
- Mancuso, M., Arnold, M., Bersano, A., Burlina, A., Chabriat, H., Debette, S., Enzinger, C., Federico, A., Filla, A., Finsterer, J., Hunt, D., Lesnik Oberstein, S., Tournier-Lasserre, E., & Markus, H. S. (2020). Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. *Eur J Neurol*, *27*(6), 909-927. <https://doi.org/10.1111/ene.14183>
- Markus, H. S., Martin, R. J., Simpson, M. A., Dong, Y. B., Ali, N., Crosby, A. H., & Powell, J. F. (2002). Diagnostic strategies in CADASIL. *Neurology*, *59*(8), 1134-1138. <https://www.ncbi.nlm.nih.gov/pubmed/12395806>
- Monet-Lepretre, M., Haddad, I., Baron-Menguy, C., Fouillot-Panchal, M., Riani, M., Domenga-Denier, V., Dussaule, C., Cognat, E., Vinh, J., & Joutel, A. (2013). Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. *Brain*, *136*(Pt 6), 1830-1845. <https://doi.org/10.1093/brain/awt092>
- Moreton, F. C., Razvi, S. S., Davidson, R., & Muir, K. W. (2014). Changing clinical patterns and increasing prevalence in CADASIL. *Acta Neurol Scand*, *130*(3), 197-203. <https://doi.org/10.1111/ane.12266>
- Mukai, M., Mizuta, I., Watanabe-Hosomi, A., Koizumi, T., Matsuura, J., Hamano, A., Tomimoto, H., & Mizuno, T. (2020). Genotype-phenotype correlations and effect of mutation location in Japanese CADASIL patients. *J Hum Genet*, *65*(8), 637-646. <https://doi.org/10.1038/s10038-020-0751-9>
- Muqtadar, H., & Testai, F. D. (2012). Single gene disorders associated with stroke: a review and update on treatment options. *Curr Treat Options Cardiovasc Med*, *14*(3), 288-297. <https://doi.org/10.1007/s11936-012-0179-4>
- Narayan, S. K., Gorman, G., Kalaria, R. N., Ford, G. A., & Chinnery, P. F. (2012). The minimum prevalence of CADASIL in northeast England. *Neurology*, *78*(13), 1025-1027. <https://doi.org/10.1212/WNL.0b013e31824d586c>
- NORD. (2019). CADASIL. <https://rarediseases.org/rare-diseases/cadasil/>
- O'Sullivan, M., Jarosz, J. M., Martin, R. J., Deasy, N., Powell, J. F., & Markus, H. S. (2001). MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. *Neurology*, *56*(5), 628-634. <https://www.ncbi.nlm.nih.gov/pubmed/11245715>
- Opherk, C., Peters, N., Herzog, J., Luedtke, R., & Dichgans, M. (2004). Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. *Brain*, *127*(Pt 11), 2533-2539. <https://doi.org/10.1093/brain/awh282>
- Orjuela, K. (2019). CADASIL. National Organization for Rare Diseases Retrieved Oct. 11, 2022 from <https://rarediseases.org/rare-diseases/cadasil/>
- Papakonstantinou, E., Bacopoulou, F., Brouzas, D., Megalooikonomou, V., D'Elia, D., Bongcam-Rudloff, E., & Vlachakis, D. (2019). NOTCH3 and CADASIL syndrome: a genetic and structural overview. *EMBNET J*, *24*. <https://doi.org/10.14806/ej.24.0.921>

Genetic Testing of CADASIL Syndrome AHS – M2069

- Pescini, F., Nannucci, S., Bertaccini, B., Salvadori, E., Bianchi, S., Ragno, M., Sarti, C., Valenti, R., Zicari, E., Moretti, M., Chiti, S., Stromillo, M. L., De Stefano, N., Dotti, M. T., Federico, A., Inzitari, D., & Pantoni, L. (2012). The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. *Stroke*, 43(11), 2871-2876. <https://doi.org/10.1161/STROKEAHA.112.665927>
- Peters, N., Opherk, C., Bergmann, T., Castro, M., Herzog, J., & Dichgans, M. (2005). Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. *Arch Neurol*, 62(7), 1091-1094. <https://doi.org/10.1001/archneur.62.7.1091>
- Ping, S., & Zhao, L.-R. (2018). *Current Understanding of Pathology and Therapeutic Status for CADASIL*. https://link.springer.com/chapter/10.1007/978-3-319-90194-7_12
- Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., Jauch, E. C., Kidwell, C. S., Leslie-Mazwi, T. M., Ovbiagele, B., Scott, P. A., Sheth, K. N., Southerland, A. M., Summers, D. V., & Tirschwell, D. L. (2019). Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*, 50(12), e344-e418. <https://doi.org/doi:10.1161/STR.0000000000000211>
- Puy, L., De Guio, F., Godin, O., Duering, M., Dichgans, M., Chabriat, H., & Jouvent, E. (2017). Cerebral Microbleeds and the Risk of Incident Ischemic Stroke in CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy). *Stroke*, 48(10), 2699-2703. <https://doi.org/10.1161/strokeaha.117.017839>
- Razvi, S. S., Davidson, R., Bone, I., & Muir, K. W. (2005). The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. *J Neurol Neurosurg Psychiatry*, 76(5), 739-741. <https://doi.org/10.1136/jnnp.2004.051847>
- Reyes, S., Kurtz, A., Herve, D., Tournier-Lasserre, E., & Chabriat, H. (2012). Presymptomatic genetic testing in CADASIL. *J Neurol*, 259(10), 2131-2136. <https://doi.org/10.1007/s00415-012-6468-8>
- Reyes, S., Viswanathan, A., Godin, O., Dufouil, C., Benisty, S., Hernandez, K., Kurtz, A., Jouvent, E., O'Sullivan, M., Czernecki, V., Boussier, M. G., Dichgans, M., & Chabriat, H. (2009). Apathy: a major symptom in CADASIL. *Neurology*, 72(10), 905-910. <https://doi.org/10.1212/01.wnl.0000344166.03470.f8>
- Rutten, J. W., Dauwerse, H. G., Gravesteijn, G., van Belzen, M. J., van der Grond, J., Polke, J. M., Bernal-Quiros, M., & Lesnik Oberstein, S. A. (2016). Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL. *Ann Clin Transl Neurol*, 3(11), 844-853. <https://doi.org/10.1002/acn3.344>
- Rutten, J. W., Haan, J., Terwindt, G. M., van Duinen, S. G., Boon, E. M., & Lesnik Oberstein, S. A. (2014). Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. *Expert Rev Mol Diagn*, 14(5), 593-603. <https://doi.org/10.1586/14737159.2014.922880>
- Rutten, J. W., & Lesnik Oberstein, S. A. J. (2016). *Cadasil* <https://www.ncbi.nlm.nih.gov/pubmed/20301673>
- Rutten, J. W., Van Eijnsden, B. J., Duering, M., Jouvent, E., Opherk, C., Pantoni, L., Federico, A., Dichgans, M., Markus, H. S., Chabriat, H., & Lesnik Oberstein, S. A. J. (2018). The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant. *Genet Med*. <https://doi.org/10.1038/s41436-018-0088-3>
- Samoës, R., Alves, J. E., Taipa, R., Silva, J., Melo Pires, M., & Pereira-Monteiro, J. M. (2016). CADASIL: MRI may be normal in the fourth decade of life - a case report. *Cephalalgia*, 36(11), 1082-1085. <https://doi.org/10.1177/0333102415618613>
- Smith, E. E., Saposnik, G., Biessels, G. J., Doubal, F. N., Fornage, M., Gorelick, P. B., Greenberg, S. M., Higashida, R. T., Kasner, S. E., Seshadri, S., American Heart Association Stroke, C., Council on Cardiovascular, R., Intervention, Council on Functional, G., Translational, B., & Council on, H. (2017). Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*, 48(2), e44-e71. <https://doi.org/10.1161/STR.0000000000000116>
- Tikka, S., Mykkanen, K., Ruchoux, M. M., Bergholm, R., Junna, M., Poyhonen, M., Yki-Jarvinen, H., Joutel, A., Viitanen, M., Baumann, M., & Kalimo, H. (2009). Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. *Brain*, 132(Pt 4), 933-939. <https://doi.org/10.1093/brain/awn364>
- Wang, M. (2018). Cadasil. *Handb Clin Neurol*, 148, 733-743. <https://doi.org/10.1016/B978-0-444-64076-5.00047-8>

Genetic Testing of CADASIL Syndrome AHS – M2069

Yin, X., Wu, D., Wan, J., Yan, S., Lou, M., Zhao, G., & Zhang, B. (2015). Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum in patients from mainland China. *Int J Neurosci*, 125(8), 585-592.

<https://doi.org/10.3109/00207454.2014.951929>

Zhu, S., & Nahas, S. J. (2016). CADASIL: Imaging Characteristics and Clinical Correlation. *Curr Pain Headache Rep*, 20(10), 57. <https://doi.org/10.1007/s11916-016-0584-6>

Medical Director review 3/2020

Specialty Matched Consultant Advisory Panel review 3/2021

Medical Director review 3/2021

Medical Director review 1/2022

Medical Director review 1/2023

Medical Director review 1/2024

Policy Implementation/Update Information

- 1/1/2019 BCBSNC will provide coverage for genetic testing of CADASIL syndrome when it is determined to be medically necessary because the criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (jd)
- 4/1/2019 Description section, policy guidelines and references updated. Medical Director review 4/2019. (jd)
- 2/11/20 Annual review by Avalon 4th Quarter CAB 2019. CPT code G0452 and code table removed from the Billing/Coding section. No change to policy intent. Medical Director review 12/2019. (jd)
- 3/31/20 Specialty Matched Consultant Advisory Panel review 3/2020. Medical Director review 3/2020. (jd)
- 2/9/21 Annual review by Avalon 4th Quarter CAB 2020. Minor revisions; no change to policy intent. Medical Director review 1/2021. (jd)
- 3/31/21 Specialty Matched Consultant Advisory Panel review 3/2021. Medical Director review 3/2021. (jd)
- 2/8/22 Reviewed by Avalon 4th Quarter 2021 CAB. Under the When Covered section, added the following to item #1 for clarity: “cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy”; no change to policy intent. Description, policy guidelines, and references updated with minor revisions. Medical Director review 1/2022. (jd)
- 2/7/23 Reviewed by Avalon 4th Quarter 2022 CAB. Description, Policy Guidelines and References sections updated. Related Policies section removed. When Covered section edited for clarity, no change to policy statement. Medical Director review 1/2023. (tm)
- 2/21/24 Reviewed by Avalon 4th Quarter 2023 CAB. Description, Policy Guidelines and References sections updated. Related Policies added to Description section. New Note 1 added to When

Genetic Testing of CADASIL Syndrome AHS – M2069

Covered section. Not Covered section edited for clarity, no change to policy statement. Medical Director review 1/2024. (tm)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.